• 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • NCT-501 Cox JD Stetz J Pajak TF Toxicity criteria of


    [13] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–6. [14] Werner-Wasik M, Axelrod RS, Friedland DP, Hauck W, Rose LJ, Chapman AE, et al. Preliminary report on NCT-501 of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy. Clin Lung Cancer 2001;2:284–9.
    [15] Machin D. Sample size tables for clinical studies. 2nd ed. NCT-501 Oxford, England: Blackwell Science; 1997. [16] Al-Sunduqchi Mahdi S. Determining the appropriate sample size for inferences based on the Wilcoxon statistics Ph.D. dissertation under the direction of William C. Guenther. Laramie, Wyoming: Dept. of Statistics, University of Wyoming; 1990. 
    [17] Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000;48:689–96.
    [18] Rodríguez N, Algara M, Foro P, Lacruz M, Reig A, Membrive I, et al. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2009;73:810–7.
    [19] Atagi S, Mizusawa J, Ishikura S, Takahashi T, Okamoto H, Tanaka H, et al. Chemoradiotherapy in elderly patients with non-small-cell lung cancer: long-term follow-up of a randomized trial (JCOG0301). Clin Lung Cancer 2018. [20] Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, et al. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation. Eur J Cancer 2013;49:2107–15.
    [21] Chen C, Uyterlinde W, Sonke JJ, de Bois J, van den Heuvel M, Belderbos J. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. Radiother Oncol 2013;108:337–41. [22] Zhu J, Zhang ZC, Li BS, Liu M, Yin Y, Yu JM, et al. Analysis of acute radiation-induced esophagitis in non-small-cell lung cancerpatients using the Lyman NTCP model. Radiother Oncol 2010;97:449–54. [23] Reuther S, Szymczak S, Raabe A, Borgmann K, Ziegler A, Petersen C, et al. Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity. Strahlenther Onkol 2015;191:59–66.
    [24] Verma V, Simone 2nd CB, Werner-Wasik M. Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer. Cancers (Basel) 2017;9:E120. [25] Pan Y, Brink C, Knap M, Khalil AA, Nyhus CH, McCulloch T, et al. Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy. Radiother Oncol 2016;118:465–70.
    [26] Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017;18:1116–25.
    [27] Devine A, Marignol L. Potential of amifostine for chemoradiotherapy and radiotherapy-associated toxicity reduction in advanced NSCLC: a meta-analysis. Anticancer Res 2016;36:5–12. [28] Lawrence YR, Paulus R, Langer C, Werner-+Wasik M, Buyyounouski MK, Komaki R, et al. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer 2013;80:298–305.